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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S486phases, we were able to encapsulate single chondrocytes in stable
monodisperse PEGDAmicrogels with a controlled diameter between 30
and 50 mm in a cell-friendly manner.
Conclusions: We have developed a microﬂuidic platform and opti-
mized the production process for the encapsulation of single chon-
drocytes in chondron-sized microgels at a typical rate of 20,000 cells
per minute. Future work will focus on the functionalization of the
microenvironment within the biomaterial by means of incorporation of
growth factors and extracellular matrix molecules to create biomimetic
and chondrogenic artiﬁcial chondrons.
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OXYGEN IS A CRITICAL PARAMETER FOR CHONDROGENIC
DIFFERENTIATION OF HUMAN UMBILICAL CORD BLOOD
MESENCHYMAL STEM CELL IN 3D-CULTURES
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Purpose: The autologous chondrocyte implantation technique presents
many limitations for cartilage disease treatment. The surgical process is
traumatic and few chondrocytes are harvested. Mesenchymal stem cells
(MSCs) represent a promising clinical tool for cartilage regeneration and
osteoarthritis (OA) therapy. Although adult bonemarrow has been up to
now the main source of MSCs, their harvest is also a highly invasive
procedure and their number, differentiation potential, and maximal life
span decline with increasing age. The umbilical cord blood mesen-
chymal stem cells (UCB-MSCs) are a promising alternative source, due
to abundant resources, painless and non-invasive collection process and
are rapidly expandable in in vitro cultures. The aim of our study was to
determine the chondrogenic differentiation potential of human UCB-
MSCs for cartilage tissue engineering.
Methods: The UCB were collected after full term and normal delivery
pregnancy. Cell ampliﬁcation, karyotype, osteoblasts and adipocytes
differentiation of UCB-MSCs were realized in normoxia. XTT cell assay
was performed after 7 days under normoxic (21% O2) or hypoxic (< 5%
O2) culture conditions. Cumulative population doublings and several
surface markers of MSCs were analyzed up to the seventh passage. The
chondrogenic differentiationwas induced using an innovative approach
combining 3D-culture in type I collagen sponges and chondrogenic
factors (BMP-2  TGF-ß1) in normoxia or in hypoxia. Chondrogenic
differentiation was then evaluated by real-time RT-PCR, Western-blot-
ting and immunoﬂuorescence microscopy after 7, 14 and 21 days of cell
differentiation. The nature of the hyaline neo-tissue obtained after 14
days of in vitro differentiation was veriﬁed by subcutaneous implan-
tation in the nude mice. The neo-tissue was collected after 35 days and
histological examination was performed using hematoxylin-eosin-
safran and alizarin red, as well as type I- and II-collagen immunohis-
tochemistry analyses.
Results: 127 UCB samples were obtained with a mean volume of 41.15
 22.95 mL. Taking into account of only those with a minimal volume
of 55 mL, the success efﬁciency was enhanced from 30% to 57%. Flow
cytometry results showed that the isolated cells expressed CD29,
CD44, CD73, CD90, CD105, CD166 and did not express CD14, CD34,
CD45, CD64 and HLA-DR. There was no signiﬁcant variation of those
markers all along cell ampliﬁcation. Otherwise, CD146 expression was
shown to be donor- and passage-dependent. Interestingly, the growth
of hypoxic UCB-MSC in monolayers induced the formation of cell
spheres and a decrease in cell metabolism. Cells were shown to dif-
ferentiate mainly in osteoblasts but not in adipocytes. The addition of
BMP-2 and TGF-ß1 allowed to enhance chondrogenesis both in nor-
moxia and hypoxia. Surprisingly, differentiation occurred earlier and at
a higher level in normoxic compared to hypoxic conditions. These
observations were conﬁrmed by the analysis of 12 chondrogenic
related genes and type II collagen protein. An increase in expression of
speciﬁc cartilage markers (SOX9, COL2A1, COLIIB, ACAN et SNORC) and a
slight MMP13 expression were observed during the culture. Otherwise,
hypoxia presented beneﬁcial effects by decreasing type X collagen. All
the neo-tissue generated in vitro and injected in mice demonstrated
that cells treated with BMP-2 and TGF-ß1 in normoxia showed a better
phenotype maintenance with a more organized and abundant type II
collagen matrix. Alizarin red staining was negative for all the donors.
Conclusions:Our experiments demonstrated that UCB-MSCs could be a
reliable cell source for cartilage tissue engineering. In this sense, wesuggest that UBC-MSCs cultured in in vitro 3D-culture can begin
chondrogenesis in normoxic conditions to obtain a more efﬁcient
chondrogenic differentiation, before placing them in hypoxic conditions
to stabilize the phenotype before in vivo implantation.
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BLOCK OF ANGIOGENESIS ENHANCES IN VIVO CHONDROGENESIS OF
NASAL CHONDROCYTES-BASED CONSTRUCTS
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Background/Aim: Vascular Endothelial Growth Factor (VEGF) is
involved in regulating cartilage growth and endochondral ossiﬁcation
during growth plate development, but also in degenerative processes
e.g. in osteoarthritis or following mechanical overloading. On the other
hand, VEGF expression is suppressed during hyaline cartilage formation
and maintenance, and blocking of angiogenesis results in improved
cartilage repair inmurinemodels. We sought to investigatewhether the
sole blockade of the endogenous VEGF pathway could improve in vivo
chondrogenesis in engineered tissues based on nasal chondrocytes
(NC). Blockage of VEGF was achieved by transducing BMSC to express
soluble VEGF receptor-2 (sFlk-1).
Methods: Human NCs were retrovirus-transduced to overexpress the
soluble form of human VEGF receptor 2 (sFlk-1). Cell-based constructs
were generated with either sFlk-1-expressing or control cells loaded on
collagen-based scaffolds. To investigate their in vivo chondrogenenic
potential, the constructs were implanted in an ectopic mouse model.
Vessel formation, VEGF activity, cartilage biochemistry and histology
were performed to evaluate how the intrinsic chondrogenic capacity of
NCs could beneﬁt from blocking VEGF pathway.
Results: The released sFlk-1 blocked blood vessel ingrowth within the
implant. Blood vessel ingrowth was signiﬁcantly reduced in the engi-
neered tissues developed by sFlk-1-expressing cells compared to con-
trol cells. sFlk-1 did not appear to regulate the in vitro chondrogenic
differentiation of NCs. However, frank chondrogenesis in vivo could
only be observed in the constructs generated by NCs expressing sFlk-1.
Cartilaginous extracellular matrix was stable up to 8 weeks in vivo.
Conclusion: VEGF blockage was sufﬁcient to induce in vivo chondro-
genesis of NC in the absence of other exogenous morphogens. The long-
term stability of the generated cartilage requires further investigations.
The overexpression of sFlk-1 and the associated reduction in blood
vessel ingrowth has profound effects on in vivo chondrogenesis by NCs,
even in the absence of chondroinductive signals at the implant site. The
absence of such effect in the in vitro model suggests a predominant
paracrine mechanism, related to the control of angiogenesis by host
cells.
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ARE UMBILICAL CORD MESENCHYMAL STEM CELLS ADVANTAGEOUS
OVER BONE MARROW MESENCHYMAL STEM CELLS FOR CELL
THERAPY IN ORTHOPAEDICS?
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Kingdom; zNatl. Ctr. for Scientiﬁc Res., Athens, Greece; xNewcastle Univ.,
Newcastle upon-tyne, United Kingdom
Purpose:Mesenchymal Stem cells (MSC) from umbilical cords (UC) are
of increasing interest for cell therapy in degenerative musculoskeletal
disorders as they present little ethical consideration and are reported to
contain immune privileged cells, which may be suitable for allogeneic
based therapies. The use of MSCs as allogeneic cells in vivo would only
be possible if they retained their immune privileged properties in an
inﬂammatory environment. We have previously shown that cells
obtained from UC are multipotent and have the recommended MSC cell
surface marker proﬁle according to the International Society for Cellular
Therapy. The focus of this study was to characterise the immune
properties of MSCs isolated from UC, particularly Wharton’s jelly (WJ)
and cells fromwhole cord (MC) as we have previously shown that cells
from these cord regions have the best multipotency. MC and WJ were
compared to Bone Marrow MSCs (BMSCs) in order to utilise the most
promising population of stem cells and to analyse the immune prop-
erties of these cells before and after stimulation with the pro-inﬂam-
matory cytokine, interferon-g (IFN-g).
